X-pert Med GmbH Report issue

For profit Phase 1 Phase 3
Founded: Grafelfing Germany (2009)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2009
NCT00372333
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

X-pert-med GmbH Munich | X-pert Med Jena

Active Ingredients

Drugs in Phase 3 Trials (1)

ketoprofen (orudis) (4 trials)

Drugs in Phase 1 Trials (5)

celecoxib (celebrex) (1 trial)

etoricoxib (Gencox) (1 trial)

ibuprofen (motrin) (1 trial)

strontium-89 (1 trial)

urea (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthralgia (Phase 3)

Erythema (Phase 1)

Inflammation (Phase 3)

Musculoskeletal Pain (Phase 3)

Myalgia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 6